Vanguard Group Inc Allogene Therapeutics, Inc. Transaction History

Vanguard Group Inc

  • $5.46 Trillion
  • Q3 2024

A detailed history of Vanguard Group Inc transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 8,327,699 shares of ALLO stock, worth $18.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,327,699
Previous 8,195,666 1.61%
Holding current value
$18.2 Million
Previous $19.1 Million 22.11%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$2.08 - $3.5 $274,628 - $462,115
132,033 Added 1.61%
8,327,699 $23.3 Million
Q2 2024

Aug 13, 2024
SELL
$2.23 - $4.38 $26,532 - $52,113
-11,898 Reduced 0.14%
8,195,666 $19.1 Million
Q1 2024

May 10, 2024
SELL
$2.92 - $5.63 $2.4 Million - $4.63 Million
-823,261 Reduced 9.12%
8,207,564 $36.7 Million
Q4 2023

Feb 14, 2024
SELL
$2.28 - $3.5 $3.55 Million - $5.45 Million
-1,556,979 Reduced 14.71%
9,030,825 $29 Million
Q3 2023

Nov 14, 2023
BUY
$3.17 - $5.96 $9.78 Million - $18.4 Million
3,086,311 Added 41.14%
10,587,804 $33.6 Million
Q2 2023

Aug 14, 2023
BUY
$4.53 - $6.74 $888,591 - $1.32 Million
196,157 Added 2.69%
7,501,493 $37.3 Million
Q1 2023

May 15, 2023
BUY
$4.92 - $8.21 $197,365 - $329,344
40,115 Added 0.55%
7,305,336 $36.1 Million
Q4 2022

Feb 10, 2023
BUY
$5.62 - $11.11 $574,021 - $1.13 Million
102,139 Added 1.43%
7,265,221 $45.7 Million
Q3 2022

Nov 14, 2022
SELL
$10.32 - $17.28 $12.8 Million - $21.5 Million
-1,243,065 Reduced 14.79%
7,163,082 $77.4 Million
Q2 2022

Aug 12, 2022
BUY
$6.78 - $12.28 $11.2 Million - $20.3 Million
1,652,167 Added 24.46%
8,406,147 $95.8 Million
Q1 2022

May 13, 2022
BUY
$7.65 - $15.29 $92,878 - $185,635
12,141 Added 0.18%
6,753,980 $61.5 Million
Q4 2021

Feb 14, 2022
BUY
$13.13 - $24.52 $605,542 - $1.13 Million
46,119 Added 0.69%
6,741,839 $101 Million
Q3 2021

Nov 12, 2021
BUY
$21.01 - $27.64 $1.96 Million - $2.58 Million
93,414 Added 1.41%
6,695,720 $172 Million
Q2 2021

Aug 13, 2021
BUY
$23.49 - $35.8 $155 Million - $236 Million
6,602,306 New
6,602,306 $172 Million

Others Institutions Holding ALLO

# of Institutions
163
Shares Held
134M
Call Options Held
59.4K
Put Options Held
113K
View Full List

About Allogene Therapeutics, Inc.

ALLO Quotes by TradingView
  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $315M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email